53 related articles for article (PubMed ID: 21323891)
1. Recombinant human CD19-ligand protein as a potent anti-leukaemic agent.
Uckun FM; Sun L; Qazi S; Ma H; Ozer Z
Br J Haematol; 2011 Apr; 153(1):15-23. PubMed ID: 21323891
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1.
Inaba H; Shimada K; Zhou YW; Ido M; Buck S; Yonehara S; Kaplan J; Komada Y
Int J Oncol; 2005 Aug; 27(2):573-9. PubMed ID: 16010441
[TBL] [Abstract][Full Text] [Related]
3. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.
Uckun FM; Qazi S; Ozer Z; Garner AL; Pitt J; Ma H; Janda KD
Br J Haematol; 2011 Jun; 153(6):741-52. PubMed ID: 21517817
[TBL] [Abstract][Full Text] [Related]
4. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH
Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
Marin V; Kakuda H; Dander E; Imai C; Campana D; Biondi A; D'Amico G
Exp Hematol; 2007 Sep; 35(9):1388-97. PubMed ID: 17656004
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ralpha chain encoding two truncated receptor proteins in relapsed childhood all.
Korte A; Köchling J; Badiali L; Eckert C; Andreae J; Geilen W; Kebelmann-Betzing C; Taube T; Wu S; Henze G; Seeger K
Cytokine; 2000 Nov; 12(11):1597-608. PubMed ID: 11052810
[TBL] [Abstract][Full Text] [Related]
8. Eradication of CD19+ leukemia by targeted calicheamicin θ.
Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
[TBL] [Abstract][Full Text] [Related]
9. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
10. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Waddick KG; Chae HP; Tuel-Ahlgren L; Jarvis LJ; Dibirdik I; Myers DE; Uckun FM
Radiat Res; 1993 Dec; 136(3):313-9. PubMed ID: 7506428
[TBL] [Abstract][Full Text] [Related]
11. Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells.
Weng WK; Shah N; O'Brien D; Van Ness B; LeBien TW
J Immunol; 1997 Dec; 159(11):5502-8. PubMed ID: 9548490
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia.
Fulda S
Br J Haematol; 2009 May; 145(4):441-54. PubMed ID: 19298593
[TBL] [Abstract][Full Text] [Related]
13. Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways.
Sanz E; Muñoz-A N; Monserrat J; Van-Den-Rym A; Escoll P; Ranz I; Alvarez-Mon M; de-la-Hera A
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5925-30. PubMed ID: 20231472
[TBL] [Abstract][Full Text] [Related]
14. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
[TBL] [Abstract][Full Text] [Related]
15. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
[TBL] [Abstract][Full Text] [Related]
16. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
17. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
18. CD5 antigen-positive B lymphocytes in human B cell ontogeny during fetal development and after autologous bone marrow transplantation.
Waddick KG; Uckun FM
Exp Hematol; 1993 Jun; 21(6):791-8. PubMed ID: 7684704
[TBL] [Abstract][Full Text] [Related]
19. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
[TBL] [Abstract][Full Text] [Related]
20. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
